Record Third-Quarter Revenue of 253.2 Billion Won
U.S. Rival Xenon Files for Approval of Competing Drug
SK Biopharmaceuticals’ Candidate to Counter Rival Drug Faces Clinical Hold

SK Biopharmaceuticals has been setting quarterly sales records with cenobamate (brand name Xcopri), its epilepsy treatment that is on track to generate KRW 800 billion in U.S. sales this year. Yet its share price has fallen nearly 40% since the start of the year. The decline is thought to reflect factors including a competing new drug with a different mechanism of action that has applied for approval in the United States, and a candidate SK Biopharmaceuticals had planned to acquire in response being held up by a clinical hold imposed by the U.S. Food and Drug Administration (FDA). With the competing drug nearing launch and the development timeline for a potential response now uncertain, the market is focusing on what will drive SK Biopharmaceuticals’ growth after cenobamate.


According to industry sources on October 21, cenobamate is expected to be covered by South Korea’s National Health Insurance as early as November, raising hopes that it will gain further market share in domestic and overseas epilepsy markets. In a report dated October 19, Hana Securities estimated SK Biopharmaceuticals’ third-quarter revenue at KRW 253.2 billion and operating profit at KRW 96.8 billion. These figures represent increases of 32% and 38%, respectively, from the same period last year.


Despite the growth outlook, the share price has instead been trending downward. SK Biopharmaceuticals closed at KRW 74,100 on October 20, down 39.7% from KRW 122,900 at the start of the year. Its market capitalization has fallen by about KRW 3.8 trillion since the beginning of the year, to KRW 5.803 trillion. Analysts say the market may be pricing in concerns that there is no visible successor to cenobamate, even as the company’s results continue to soar. Cenobamate’s U.S. sales totaled KRW 224.4 billion, accounting for 91% of the KRW 247.4 billion in consolidated revenue in the second quarter.


"Why Is the Stock Falling Despite Such Strong Results?"... SK Biopharmaceuticals' 'Next Cenobamate' Put to the Test View original image

Meanwhile, a competing new drug has emerged in the United States. Canadian company Xenon Pharmaceuticals applied to the FDA in September for approval of azetukalner, a next-generation epilepsy drug with a different mechanism of action from cenobamate. In a Phase 3 trial, nearly 60% of participants were taking cenobamate or had taken it and then discontinued treatment; azetukalner reduced seizure frequency by more than half (53.2%). Last month, Xenon Chief Financial Officer (CFO) Tucker Kelly said, “Cenobamate is essentially the only branded drug left in the U.S. epilepsy market,” and said the company would price azetukalner higher.


In August, SK Biopharmaceuticals agreed to acquire opakalim from U.S. biotech company Biohaven for up to $795 million (approximately KRW 1.0549 trillion) as a candidate to compete with azetukalner, but the two companies have yet to finalize the deal nearly two months later. Like azetukalner, opakalim is designed to open potassium channels while reducing dizziness and drowsiness. Just nine days after the agreement, the FDA halted enrollment of new patients in opakalim’s Phase 2 and Phase 3 clinical trials. Abnormal findings emerged in a toxicity study in which rats were administered a substance produced when opakalim breaks down in the body (a metabolite), and the FDA requested additional data to determine whether the same problem could occur in humans. SK Biopharmaceuticals has not yet paid the upfront fee and is discussing with Biohaven an arrangement under which it would pay and take over the rights after the hold is lifted.



"Why Is the Stock Falling Despite Such Strong Results?"... SK Biopharmaceuticals' 'Next Cenobamate' Put to the Test View original image

SK Biopharmaceuticals is working to expand the market for cenobamate while accelerating efforts to identify new growth opportunities. Earlier this month, it completed a Phase 3 trial of cenobamate in pediatric patients and began pursuing an expansion of the drug’s indications. Recently, it abolished the chief technology officer (CTO) position that had overseen research and development and reorganized its R&D division around leaders responsible for individual fields, including neuroscience, radiopharmaceuticals (RPT), and targeted protein degradation. In its core neuroscience field, the company brought in division head Kim Tae-ho, who led neuroscience R&D at Novartis for 12 years, and reorganized the division to report directly to the CEO. An SK Biopharmaceuticals representative said, “The reorganization is intended to build expertise in each field.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing